trending Market Intelligence /marketintelligence/en/news-insights/trending/acowhar7xtzketmvmwt5ga2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Therapure Biopharma's biologics unit plans IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Therapure Biopharma's biologics unit plans IPO

Therapure Biopharma Inc..'s biologics division, Evolve Biologics, confidentially submitted a draft registration statement for an IPO in the U.S.

The IPO is expected to commence after the U.S. Securities and Exchange Commission completes its review process, subject to market and other conditions.

The Mississauga, Canada-based privately held company's biologics unit separates proteins from blood's plasma for use in treating diseases.